Interview With Janssen Doctor Explores Potential Bladder Cancer

Every year, roughly 80,000 Americans receive a bladder cancer diagnosis. Many endure difficult and burdensome treatments in an attempt to fight the disease. But new innovations just might change that.

Replay, Ask Me Anything About Myeloma: Beth Faiman

FOXA1 repression drives lineage plasticity and immune heterogeneity in bladder cancers with squamous differentiation

Role of biomarkers, targeted therapy and tumour mutations in the landscape of bladder cancer - ecancer

Interview With Janssen Doctor Explores Potential Bladder Cancer Treatment Options

Recurrence mechanisms of non-muscle-invasive bladder cancer — a clinical perspective

Ícaro Taynan (him/his) on LinkedIn: #janssen #jobsinuk #oncology #medicallead #medicalaffairs…

Bladder Cancer Drugs Market Size, Share, Global Industry Forecast To 2033

Cancers, Free Full-Text

Johnson & Johnson on LinkedIn: Dr. Paul Janssen Award

News from the Faculty of Farmacy - Department of Medicinal Chemistry - Uppsala University, Sweden

Genomic heterogeneity in bladder cancer: challenges and possible solutions to improve outcomes

The Fascinating Story Behind a New Bladder Cancer Treatment

Improving dialogue between healthcare professionals and patients in bladder cancer